Viridian Therapeutics (VRDN) Projected to Release Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($1.02) per share and revenue of $4.72 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The company had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. On average, analysts expect Viridian Therapeutics to post ($4.07) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $24.67 on Monday. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43. The firm has a market cap of $2.79 billion, a PE ratio of -7.32 and a beta of 1.07. The company’s fifty day simple moving average is $21.66 and its 200 day simple moving average is $21.95. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29.

Insider Activity

In related news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Royal Bank Of Canada upped their price objective on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Weiss Ratings raised shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Truist Financial raised their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen lowered Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.92.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.